Skip to main content

Table 3 Summary results of the base-case cost-effectiveness analysis. Abbreviations: QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio

From: Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients

 

IDegLira vs. Liraglutide

IDegLira vs. degludec

ΔQALY

0.073

0.068

ΔCOST

-27,945

-1196

ICER

Dominant

Dominant

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us